BioWest Therapeutics Inc., Suite 1320, 885 West Georgia, Vancouver, British Columbia, Canada V6C 2G2.
Antimicrob Agents Chemother. 2011 Aug;55(8):3720-8. doi: 10.1128/AAC.00322-11. Epub 2011 May 16.
MX-2401 is an expanded-spectrum lipopeptide antibiotic selective for Gram-positive bacteria that is a semisynthetic analog of the naturally occurring lipopeptide amphomycin. It was active against Enterococcus spp., including vancomycin-sensitive Enterococcus (VSE), vanA-, vanB-, and vanC-positive vancomycin-resistant Enterococcus (VRE), linezolid- and quinupristin-dalfopristin-resistant isolates (MIC(90) of 4 μg/ml), methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive S. aureus (MSSA) (MIC(90) of 2 μg/ml), coagulase-negative staphylococci, including methicillin-sensitive Staphylococcus epidermidis (MSSE) and methicillin-resistant S. epidermidis (MRSE) (MIC(90) of 2 μg/ml), and Streptococcus spp. including viridans group streptococci, and penicillin-resistant, penicillin-sensitive, penicillin-intermediate and macrolide-resistant isolates of Streptococcus pneumoniae (MIC(90) of 2 μg/ml). MX-2401 demonstrated a dose-dependent postantibiotic effect varying from 1.5 to 2.4 h. Furthermore, MX-2401 was rapidly bactericidal at 4 times the MIC against S. aureus and Enterococcus faecalis, with more than 99.9% reduction in viable bacterial attained at 4 and 24 h, respectively. The MICs of MX-2401 against MRSA, MSSA, VSE, and VRE strains serially exposed for 15 passages to sub- to supra-MICs of MX-2401 remained within three dilutions of the original MIC. In contrast to that of the lipopeptide daptomycin, the antibacterial activity of MX-2401 was not affected in vitro by the presence of lung surfactant, and MX-2401 was active in vivo in the bronchial-alveolar pneumonia mouse model, in which daptomycin failed to show any activity. Moreover, the activity of MX-2401 was not as strongly dependent on the Ca(2+) concentration as is the activity of daptomycin. In conclusion, MX-2401 is a promising new-generation lipopeptide for the treatment of serious infections with Gram-positive bacteria, including hospital-acquired pneumonia.
MX-2401 是一种广谱脂肽类抗生素,对革兰氏阳性菌具有选择性,是天然脂肽类抗生素安普霉素的半合成类似物。它对肠球菌属具有活性,包括万古霉素敏感肠球菌(VSE)、vanA、vanB 和 vanC 阳性万古霉素耐药肠球菌(VRE)、利奈唑胺和奎奴普丁/达福普汀耐药分离株(MIC90 为 4μg/ml)、耐甲氧西林金黄色葡萄球菌(MRSA)和甲氧西林敏感金黄色葡萄球菌(MSSA)(MIC90 为 2μg/ml)、凝固酶阴性葡萄球菌,包括甲氧西林敏感表皮葡萄球菌(MSSE)和耐甲氧西林表皮葡萄球菌(MRSE)(MIC90 为 2μg/ml)以及链球菌属,包括草绿色链球菌以及青霉素耐药、青霉素敏感、青霉素中介和大环内酯类耐药肺炎链球菌分离株(MIC90 为 2μg/ml)。MX-2401 表现出剂量依赖性的抗生素后效应,范围为 1.5 至 2.4 小时。此外,MX-2401 对金黄色葡萄球菌和粪肠球菌具有快速杀菌作用,在 4 倍 MIC 时,4 小时和 24 小时时分别有超过 99.9%的活菌减少。在 15 次传代至 MX-2401 的亚 MIC 至超 MIC 水平的过程中,MRSA、MSSA、VSE 和 VRE 菌株对 MX-2401 的 MIC 仍保持在原始 MIC 的三个稀释度内。与脂肽类达托霉素不同,肺表面活性剂的存在并不影响 MX-2401 的体外抗菌活性,并且 MX-2401 在支气管肺泡肺炎小鼠模型中具有活性,而达托霉素在该模型中则没有任何活性。此外,MX-2401 的活性不像达托霉素那样强烈依赖于 Ca2+浓度。总之,MX-2401 是一种有前途的新型脂肽类抗生素,可用于治疗革兰氏阳性菌引起的严重感染,包括医院获得性肺炎。